Humacyte’s (HUMA) Buy Rating Reiterated at D. Boral Capital
Humacyte (NASDAQ:HUMA – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $25.00 price target on the stock. Other equities analysts also recently issued reports about the stock. Benchmark reaffirmed a “buy” rating on shares of Humacyte […]
Humacyte (NASDAQ:HUMA – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $25.00 price target on the stock. Other equities analysts also recently issued reports about the stock. Benchmark reaffirmed a “buy” rating on shares of Humacyte […]
